📬 Melanoma Intelligence Digest — Week 2026-W43
Melanoma week centered on ESMO 2026 pre-reads for the Phase III INTerpath-001 mRNA vaccine, a JITC real-world analysis of adjuvant therapy in patients 75+, new relapse-pattern data from the Spanish Melanoma Registry, FIRELIGHT-1 tovorafenib results in BRAF/CRAF-altered tumors, and a retrospective readout on post-discharge safety of lifileucel.
⚡ TL;DR
🐦 Twitter / 🦋 Bluesky
Full details below ↓
📄 What's Being Published
No new manuscripts cleared the relevance bar this week.
🗂 Every paper considered this week, including the ones that didn’t make it →
🗣️ What People Were Discussing This Week
How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).
Update: JITC adjuvant-in-elderly analysis publishes, and the debate shifts to who never gets treated at relapse
The real-world retrospective study is now out in JITC. It covers 580 patients aged 75+ with resected stage III/IV melanoma across 14 international centers, a group that trials barely include. Adjuvant therapy was associated with better melanoma-specific, overall and recurrence-free survival. However, 55% stopped early, and the authors caution that the hazard ratios are an upper bound because fitter patients received adjuvant treatment. The sharper issue is what happens under observation: 69% recurred but only 47% got first-line systemic therapy. Clinicians are therefore asking whether deferral is defensible when treatment at relapse often never arrives, and whether access, fitness and post-relapse care drive outcomes more than age itself.
Key numbers: 5-yr MSS 74% vs 60%, HR 0.58 · OS HR 0.66 · RFS HR 0.57 · Grade ≥2 irAEs 42% · MSS recurrence-free or treated at relapse, HR 0.83
Discussed by: @YGaritaonaindia, @MarioBalsaMD, @Lucarecco, @sitcancer
→ View representative tweet
Sources cited: Impact of adjuvant therapy on melanoma-specific survival in elderly patients with high-ri… (Journal for ImmunoTherapy of Cancer, 2026)
Review maps post-checkpoint melanoma strategies, sorting randomized phase III evidence from single-arm cohorts
A new narrative review in Cancer Treat Res Commun maps four emerging strategies after PD-1, CTLA-4 and LAG-3 against the resistance mechanisms they target. The four strategies are vaccines, intralesional therapy, cell therapy and T-cell engagers. Among intralesional options, daromun improves RFS/DMFS, and RP1 plus nivolumab now has FDA accelerated approval. Among T-cell engagers, tebentafusp already changes OS in uveal melanoma, and PRAME-directed strategies are moving into phase III. V940 plus pembrolizumab is flagged only as possibly promising. The authors stress that the evidence ranges from randomized phase III data to small single-arm cohorts. That leaves open which second-line platform after PD-1 plus CTLA-4 or LAG-3 is strong enough to use outside a trial: intralesional therapy, TIL, or a T-cell engager.
Discussed by: @boutrosand, @MarioBalsaMD
→ View representative tweet
Sources cited: ScienceDirect
Update: INTerpath-001 full Phase III data set for 24 October ESMO Presidential Symposium, with magnitude of benefit still unreported
INTerpath-001 is a Phase III trial of intismeran autogene (V940), an mRNA-based individualized neoantigen therapy, plus pembrolizumab in 1,137 patients with resected stage IIB–IV melanoma. The trial has met its RFS and DMFS endpoints, but the effect size is undisclosed until the LBA1 presentation on 24 October 2026 in Presidential Symposium I. Specialists rank it their top ESMO 2026 trial to watch. They are framing the question around how much the vaccine adds to pembrolizumab, against the Phase IIb KEYNOTE-942 benchmark of RFS HR 0.51 and DMFS HR 0.41. If benefit is confirmed, the debate is which patients justify the current six-week personalized manufacturing wait.
Discussed by: @ChandrakanthMv, @aftimosp, @MarioBalsaMD, @mateosagan, @SmilowCancer
→ View representative tweet
Sources cited: Merck press release
Spanish Melanoma Registry: stage I primaries relapse latest but with the most brain metastases and the shortest survival
A JAAD analysis of 365 patients from the Spanish Melanoma Registry found that stage I primaries relapsed latest, at a median of 52 months. Their relapses more often involved brain metastases, and survival after relapse was the shortest of any stage. The authors summarize this as low risk at diagnosis not equaling low risk at relapse. The open question is whether resected stage I patients warrant longer or brain-inclusive surveillance.
Key numbers: Brain mets at stage I relapse OR 4.0 · Post-relapse mOS 19.8 vs 43 mo (stage I vs stage III)
Discussed by: @YGaritaonaindia, @MarioBalsaMD
→ View representative tweet
Sources cited: ScienceDirect
Prepared by Rafael Santana-Davila, M.D. Questions or feedback? Just reply to this email.
Disclaimer: This digest is AI-generated. Content may contain errors -- always verify with original sources.
